PDCD1 and cancer: In a mice model, TNF inhibitors concomitantly with combined CTLA-4 and PD-1 immunotherapy ameliorated colitis and improved antitumor efficacy, which provided clinically feasible strategies to dissociate efficacy and toxicity for cancer immunotherapy (Perez-Ruiz et al., 2019).